|
| Exchange Disseminated Time | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 30, 2014, inter alia, considered and approved the following matters subject to the consent of members to be taken through Postal Ballot as per the provisions of the Companies Act, 2013 and Rules thereof:
a. Raising of funds for an amount not exceeding USD 300 Mn. through issuance of securities including Equity Shares or equity linked securities, including through a qualified institutions placement under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (the "SEBI ICDR Regulations"), and / or issuance of Equity Shares through convertible bonds, depository receipts and / or any other instrument convertible or exchangeable into Equity Shares, and / or other securities with or without warrants, to eligible investors subject to the approval of the members of the Company pursuant to the provisions of Section 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013, and the provisions of the Memorandum and Articles of Association of the Company, the Listing Agreements and in accordance with the SEBI ICDR Regulations and in such manner and on such price, terms and conditions as may be determined by the Board or a duly appointed committee of the Board in accordance with the SEBI ICDR Regulations and / or other applicable provisions of the law.
b. Increase in the investment limits of Foreign Institutional Investors (FIIs) from 40% to 55% in terms of Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000 (as amended). |
|
|